Cinclus Pharma
18.43
SEK
+1.94 %
CINPHA
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Less than 1K followers
+1.94%
-13.8%
-10.1%
-27.81%
-41.86%
-
-
-
-43.47%
Cinclus Pharma is a Swedish pharmaceutical company in the clinical phase. The company is active in the development of molecules for the treatment of acid-related diseases. The company's leading drug candidate linaprazan glurate is being developed for the treatment of severe gastroesophageal reflux disease (GERD). Cinclus Pharma was founded in 2014 and has its headquarters in Stockholm.
Read moreMarket cap
873.44M SEK
Turnover
845.61K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Financial calendar
20.2
2025
Annual report '24
19.5
2025
Interim report Q1'25
22.5
2025
General meeting '25
ShowingAll content types
Linaprazan glurate receives marketing approval in China
Issue and repurchase of class C shares
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools